Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of September 2021. The report, dated September 17, 2021, serves primarily as a vehicle to submit a press release (Exhibit 99.1) to the U.S. Securities and Exchange Commission. The registrant is headquartered in Marseille, France, and files annual reports under Form 20-F.
Key Financial Metrics
The filing text provided does not contain specific financial data. There are no disclosed values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The content is limited to the cover page and exhibit index.
Material Changes
No material changes to financial position or operations are detailed in the provided text. The filing references a press release dated September 17, 2021, but the content of that release is not included in the source text.
Guidance, Outlook, and Risks
The document does not provide management commentary, forward-looking guidance, risk factors, or details on contingencies. The only substantive reference is the inclusion of a press release, the specifics of which are absent from this summary.
Investor Verification Checklist
- Verify the content of the referenced Press Release dated September 17, 2021 (Exhibit 99.1), as the filing itself contains no operational details.
- Confirm the company's status as a Form 20-F filer for annual reporting.
- Check subsequent filings for financial metrics, as this 6-K does not report quantitative data.